9.90

0.92% 0.13

Design Therapeutics Inc (DSGN)

Overview News Price History Option Chain Financials Discussions Forecast

Design Therapeutics Inc stock is traded at $9.90, with a volume of 7,453. It is up +0.92% in the last 24 hours and up +50.53% over the past month. Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Previous Close:

$9.77

Open:

$9.89

24h Volume:

7,453

Relative Volume:

0.03

Market Cap:

$563.94M

Revenue:

Net Income/Loss:

$-66.86M

P/E Ratio:

-8.25

EPS:

-1.2

Net Cash Flow:

$-58.82M

1W Performance:

+5.01%

1M Performance:

+50.53%

6M Performance:

+146.50%

1Y Performance:

+59.55%

1-Day Range:

$9.69

$9.90

1-Week Range:

$8.58

$10.02

52-Week Range:

$2.60

$10.02

Design Therapeutics Inc Stock (DSGN) Company Profile

Name

Design Therapeutics Inc

Sector

Healthcare (1134)

Industry

Biotechnology (632)

Phone

858-293-4900

Address

6005 HIDDEN VALLEY ROAD, CARLSBAD

Employee

Twitter

Next Earnings Date

2025-03-10

Latest SEC Filings

DSGN's Discussions on Twitter

Compare DSGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DSGN Design Therapeutics Inc	9.90	559.38M	0	-66.86M	-58.82M	-1.20
VRTX Vertex Pharmaceuticals Inc	461.75	116.04B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	734.14	75.97B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	467.05	61.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	915.48	56.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.65	43.73B	447.02M	-1.18B	-906.14M	-6.1812

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Initiated	Craig Hallum	Buy
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-20-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral
May-04-23	Upgrade	Goldman	Sell → Neutral
Jun-10-22	Initiated	Wedbush	Outperform
May-02-22	Initiated	RBC Capital Mkts	Outperform
Jan-19-22	Initiated	Goldman	Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-20-21	Initiated	Piper Sandler	Overweight
Apr-20-21	Initiated	SVB Leerink	Outperform

View All

Design Therapeutics Inc Stock (DSGN) Latest News

06:45 AM

Design Therapeutics (NASDAQ:DSGN) Raised to "Strong-Buy" at Craig Hallum - MarketBeat

06:45 AM

01:59 AM

Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World

01:59 AM

01:35 AM

Why retail investors pile into Design Therapeutics Inc. stock2025 Technical Overview & Weekly High Return Stock Forecasts - Newser

01:35 AM

Dec 04, 2025

Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat

Dec 04, 2025

Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat

Dec 04, 2025

How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser

Dec 04, 2025

Dec 03, 2025

Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria

Dec 03, 2025

Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq

Dec 03, 2025

Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com

Dec 03, 2025